Axsome Therapeutics
American biopharmaceutical firm, Axsome Therapeutics, develops therapies for pain and neurological disorders globally.
Founded
2012American biopharmaceutical firm, Axsome Therapeutics, develops therapies for pain and neurological disorders globally.
Axsome Therapeutics, founded with a mission to significantly improve patient lives, is an American biopharmaceutical company focused on developing therapies for pain and neurological disorders. The company’s innovative pipeline includes treatments for central nervous system (CNS) conditions such as depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome serves a global market, aiming to address unmet medical needs with its cutting-edge therapeutic solutions.
Notable figures affiliated with Axsome Therapeutics include key investors and industry experts who have supported the company's growth and innovation. The company has achieved significant milestones, including advancing multiple drug candidates through clinical trials and receiving regulatory approvals. Axsome's impact is reflected in its commitment to addressing complex CNS conditions, thereby improving the quality of life for patients worldwide.
Companies similar to Axsome Therapeutics include Axonis Therapeutics, Axial Therapeutics, Amylyx Pharmaceuticals and NeuroTherapeutics Pharma.
Axsome Therapeutics was founded in 2012.
Axsome Therapeutics' headquarters is located in New York City, NY, US.
Axsome Therapeutics' most recent funding round was for $225M (USD) in June 2023.
As of Jun 28, 2023, Axsome Therapeutics has disclosed funding of $432M (USD). Undisclosed round amounts are excluded.
Axsome Therapeutics has 383 employees as of Feb 6, 2024.
NeuroTherapeutics Pharma
